<DOC>
	<DOCNO>NCT01442129</DOCNO>
	<brief_summary>The main purpose research determine whether inject mesenchymal precursor cell ( MPC ) heart surgery implant leave ventricular assist device ( LVAD ) safe . MPCs normally present human bone marrow , show increase development blood vessel new heart muscle cell heart . In addition , research do test whether inject MPCs heart effective improve heart function .</brief_summary>
	<brief_title>The Effect Intramyocardial Injection Mesenchymal Precursor Cells Myocardial Function Patients Undergoing LVAD Implantation</brief_title>
	<detailed_description>Intramyocardial injection mesenchymal precursor cell ( MPC ) patient advanced heart failure treat leave ventricular assist device ( LVAD ) implantation may result renewable source proliferate functional cardiomyocytes , well induce development capillary large size blood vessel supply oxygen nutrient endogenous myocardium newly-implanted cardiomyocytes , release factor capable paracrine signaling . If safety establish efficacy signal observe exploratory trial , investigator design follow-up trial ( stage 2 ) base adaptive design . The next trial would randomize patient active therapy one two dos ( 25 75 million MPCs ) versus placebo , base predetermined selection criterion drop randomization one dose arm result accrue . Should exploratory trial demonstrate safety signal efficacy , subsequent trial would base single dose 75 million MPCs versus placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Signed informed consent , inclusive release medical information , Health Insurance Portability Accountability Act ( HIPAA ) documentation ; Age 18 year old ; If subject partner childbearing potential , must willing use adequate contraception ( hormonal barrier method abstinence ) time screen period least 16 week procedure ; Female subject childbearing potential must negative serum pregnancy test screening ; Admitted clinical center time randomization ; Clinical indication accept candidate implantation FDA approve implantable , nonpulsatile LVAD bridge transplantation destination therapy . Planned percutaneous LVAD implantation ; Anticipated requirement biventricular mechanical support ; Cardiothoracic surgery within 30 day prior randomization ; Myocardial infarction within 30 day prior randomization ; Prior cardiac transplantation , LV reduction surgery , cardiomyoplasty ; Acute reversible cause heart failure ( e.g . myocarditis , profound hypothyroidism ) ; Stroke within 30 day prior randomization ; Platelet count &lt; 100,000/ul within 24 hour prior randomization ; Active systemic infection within 48 hour prior randomization ; Presence &gt; 10 % antihuman leukocyte antigen ( antiHLA ) antibody titer know specificity MPC donor HLA antigens ; A know hypersensitivity dimethyl sulfoxide ( DMSO ) , murine , and/or bovine product ; History cancer prior screen ( exclude basal cell carcinoma ) ; Acute chronic infectious disease , include limited human immunodeficiency virus ( HIV ) ; Received investigational intervention within 30 day prior randomization ; Treatment and/or incompleted followup treatment investigational cell base therapy within 6 month prior randomization ; Active participation research therapy cardiovascular repair/regeneration ; Prior recipient stem precursor cell therapy cardiac repair ; Pregnant breastfeeding time randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Left Ventricular Assist Device</keyword>
	<keyword>Heart Transplantation</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Destination Therapy</keyword>
	<keyword>Cell Therapy</keyword>
</DOC>